Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 86

1.

A novel FTY720 analogue targets SET-PP2A interaction and inhibits growth of acute myeloid leukemia cells without inducing cardiac toxicity.

Vicente C, Arriazu E, Martínez-Balsalobre E, Peris I, Marcotegui N, García-Ramírez P, Pippa R, Rabal O, Oyarzábal J, Guruceaga E, Prósper F, Mateos MC, Cayuela ML, Odero MD.

Cancer Lett. 2019 Oct 5. pii: S0304-3835(19)30498-7. doi: 10.1016/j.canlet.2019.10.007. [Epub ahead of print]

PMID:
31593801
2.

Comment on "PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL human leukemia".

Perrotti D, Agarwal A, Lucas CM, Narla G, Neviani P, Odero MD, Ruvolo PP, Verrills NM.

Sci Transl Med. 2019 Jul 17;11(501). pii: eaau0416. doi: 10.1126/scitranslmed.aau0416.

PMID:
31316003
3.

Role of drug transporters in the sensitivity of acute myeloid leukemia to sorafenib.

Macias RIR, Sánchez-Martín A, Rodríguez-Macías G, Sánchez-Abarca LI, Lozano E, Herraez E, Odero MD, Díez-Martín JL, Marin JJG, Briz O.

Oncotarget. 2018 Jun 19;9(47):28474-28485. doi: 10.18632/oncotarget.25494. eCollection 2018 Jun 19.

4.

The MDS and EVI1 complex locus (MECOM) isoforms regulate their own transcription and have different roles in the transformation of hematopoietic stem and progenitor cells.

Maicas M, Vázquez I, Alis R, Marcotegui N, Urquiza L, Cortés-Lavaud X, Cristóbal I, García-Sánchez MA, Odero MD.

Biochim Biophys Acta Gene Regul Mech. 2017 Jun;1860(6):721-729. doi: 10.1016/j.bbagrm.2017.03.007. Epub 2017 Apr 6.

PMID:
28391050
5.

Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition.

Mateo F, Arenas EJ, Aguilar H, Serra-Musach J, de Garibay GR, Boni J, Maicas M, Du S, Iorio F, Herranz-Ors C, Islam A, Prado X, Llorente A, Petit A, Vidal A, Català I, Soler T, Venturas G, Rojo-Sebastian A, Serra H, Cuadras D, Blanco I, Lozano J, Canals F, Sieuwerts AM, de Weerd V, Look MP, Puertas S, García N, Perkins AS, Bonifaci N, Skowron M, Gómez-Baldó L, Hernández V, Martínez-Aranda A, Martínez-Iniesta M, Serrat X, Cerón J, Brunet J, Barretina MP, Gil M, Falo C, Fernández A, Morilla I, Pernas S, Plà MJ, Andreu X, Seguí MA, Ballester R, Castellà E, Nellist M, Morales S, Valls J, Velasco A, Matias-Guiu X, Figueras A, Sánchez-Mut JV, Sánchez-Céspedes M, Cordero A, Gómez-Miragaya J, Palomero L, Gómez A, Gajewski TF, Cohen EEW, Jesiotr M, Bodnar L, Quintela-Fandino M, López-Bigas N, Valdés-Mas R, Puente XS, Viñals F, Casanovas O, Graupera M, Hernández-Losa J, Ramón Y Cajal S, García-Alonso L, Saez-Rodriguez J, Esteller M, Sierra A, Martín-Martín N, Matheu A, Carracedo A, González-Suárez E, Nanjundan M, Cortés J, Lázaro C, Odero MD, Martens JWM, Moreno-Bueno G, Barcellos-Hoff MH, Villanueva A, Gomis RR, Pujana MA.

Oncogene. 2017 May 11;36(19):2737-2749. doi: 10.1038/onc.2016.427. Epub 2016 Dec 19.

6.

Combined targeting of SET and tyrosine kinases provides an effective therapeutic approach in human T-cell acute lymphoblastic leukemia.

Richard NP, Pippa R, Cleary MM, Puri A, Tibbitts D, Mahmood S, Christensen DJ, Jeng S, McWeeney S, Look AT, Chang BH, Tyner JW, Vitek MP, Odero MD, Sears R, Agarwal A.

Oncotarget. 2016 Dec 20;7(51):84214-84227. doi: 10.18632/oncotarget.12394.

7.

MYC-dependent recruitment of RUNX1 and GATA2 on the SET oncogene promoter enhances PP2A inactivation in acute myeloid leukemia.

Pippa R, Dominguez A, Malumbres R, Endo A, Arriazu E, Marcotegui N, Guruceaga E, Odero MD.

Oncotarget. 2016 Jun 6;8(33):53989-54003. doi: 10.18632/oncotarget.9840. eCollection 2017 Aug 15.

8.

Protein Phosphatase 2A as a Therapeutic Target in Acute Myeloid Leukemia.

Arriazu E, Pippa R, Odero MD.

Front Oncol. 2016 Apr 6;6:78. doi: 10.3389/fonc.2016.00078. eCollection 2016. Review.

9.

Lipid Nanosystems Enhance the Bioavailability and the Therapeutic Efficacy of FTY720 in Acute Myeloid Leukemia.

Estella-Hermoso de Mendoza A, Castello-Cros R, Imbuluzqueta E, Cirauqui C, Pippa R, Odero MD, Blanco-Prieto MJ.

J Biomed Nanotechnol. 2015 Apr;11(4):691-701.

PMID:
26310075
10.

New insights on the transcriptional regulation of CD69 gene through a potent enhancer located in the conserved non-coding sequence 2.

Laguna T, Notario L, Pippa R, Fontela MG, Vázquez BN, Maicas M, Aguilera-Montilla N, Corbí ÁL, Odero MD, Lauzurica P.

Mol Immunol. 2015 Aug;66(2):171-9. doi: 10.1016/j.molimm.2015.02.031. Epub 2015 Mar 22.

11.

CIP2A high expression is a poor prognostic factor in normal karyotype acute myeloid leukemia.

Barragán E, Chillón MC, Castelló-Cros R, Marcotegui N, Prieto MI, Hoyos M, Pippa R, Llop M, Etxabe A, Cervera J, Rodríguez G, Buño I, Rifón J, Sierra J, González M, Calasanz MJ, Sanz MA, Odero MD.

Haematologica. 2015 May;100(5):e183-5. doi: 10.3324/haematol.2014.118117. Epub 2015 Jan 30. No abstract available.

12.

GATA2 germline mutations impair GATA2 transcription, causing haploinsufficiency: functional analysis of the p.Arg396Gln mutation.

Cortés-Lavaud X, Landecho MF, Maicas M, Urquiza L, Merino J, Moreno-Miralles I, Odero MD.

J Immunol. 2015 Mar 1;194(5):2190-8. doi: 10.4049/jimmunol.1401868. Epub 2015 Jan 26.

13.

Importance of genetics in acute myeloid leukemia.

Pippa R, Odero MD.

An Sist Sanit Navar. 2014 Sep-Dec;37(3):429-34. Review.

14.

Effect of FTY720 on the SET-PP2A complex in acute myeloid leukemia; SET binding drugs have antagonistic activity.

Pippa R, Dominguez A, Christensen DJ, Moreno-Miralles I, Blanco-Prieto MJ, Vitek MP, Odero MD.

Leukemia. 2014 Sep;28(9):1915-8. doi: 10.1038/leu.2014.141. Epub 2014 Apr 30. No abstract available.

PMID:
24781014
15.

Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia.

Agarwal A, MacKenzie RJ, Pippa R, Eide CA, Oddo J, Tyner JW, Sears R, Vitek MP, Odero MD, Christensen DJ, Druker BJ.

Clin Cancer Res. 2014 Apr 15;20(8):2092-103. doi: 10.1158/1078-0432.CCR-13-2575. Epub 2014 Jan 16.

16.

Hypermethylation of the alternative AWT1 promoter in hematological malignancies is a highly specific marker for acute myeloid leukemias despite high expression levels.

Guillaumet-Adkins A, Richter J, Odero MD, Sandoval J, Agirre X, Catala A, Esteller M, Prósper F, Calasanz MJ, Buño I, Kwon M, Court F, Siebert R, Monk D.

J Hematol Oncol. 2014 Jan 9;7:4. doi: 10.1186/1756-8722-7-4.

17.

Downregulation of PPP2R5E is a common event in acute myeloid leukemia that affects the oncogenic potential of leukemic cells.

Cristóbal I, Cirauqui C, Castello-Cros R, Garcia-Orti L, Calasanz MJ, Odero MD.

Haematologica. 2013 Sep;98(9):e103-4. doi: 10.3324/haematol.2013.084731. Epub 2013 Jun 28. No abstract available.

18.

Edelfosine lipid nanosystems overcome drug resistance in leukemic cell lines.

Lasa-Saracíbar B, Estella-Hermoso de Mendoza A, Mollinedo F, Odero MD, Blanco-Príeto MJ.

Cancer Lett. 2013 Jul 1;334(2):302-10. doi: 10.1016/j.canlet.2013.01.018. Epub 2013 Jan 23.

19.

Integration of SNP and mRNA arrays with microRNA profiling reveals that MiR-370 is upregulated and targets NF1 in acute myeloid leukemia.

García-Ortí L, Cristóbal I, Cirauqui C, Guruceaga E, Marcotegui N, Calasanz MJ, Castello-Cros R, Odero MD.

PLoS One. 2012;7(10):e47717. doi: 10.1371/journal.pone.0047717. Epub 2012 Oct 15.

20.

Mutation patterns of 16 genes in primary and secondary acute myeloid leukemia (AML) with normal cytogenetics.

Fernandez-Mercado M, Yip BH, Pellagatti A, Davies C, Larrayoz MJ, Kondo T, Pérez C, Killick S, McDonald EJ, Odero MD, Agirre X, Prósper F, Calasanz MJ, Wainscoat JS, Boultwood J.

PLoS One. 2012;7(8):e42334. doi: 10.1371/journal.pone.0042334. Epub 2012 Aug 9.

21.

Functional characterization of the promoter region of the human EVI1 gene in acute myeloid leukemia: RUNX1 and ELK1 directly regulate its transcription.

Maicas M, Vázquez I, Vicente C, García-Sánchez MA, Marcotegui N, Urquiza L, Calasanz MJ, Odero MD.

Oncogene. 2013 Apr 18;32(16):2069-78. doi: 10.1038/onc.2012.222. Epub 2012 Jun 11.

PMID:
22689058
22.

Epigenetic regulation of miRNA genes in acute leukemia.

Agirre X, Martínez-Climent JÁ, Odero MD, Prósper F.

Leukemia. 2012 Mar;26(3):395-403. doi: 10.1038/leu.2011.344. Epub 2011 Dec 6. Review.

PMID:
22143672
23.

Overexpression of SET is a recurrent event associated with poor outcome and contributes to protein phosphatase 2A inhibition in acute myeloid leukemia.

Cristóbal I, Garcia-Orti L, Cirauqui C, Cortes-Lavaud X, García-Sánchez MA, Calasanz MJ, Odero MD.

Haematologica. 2012 Apr;97(4):543-50. doi: 10.3324/haematol.2011.050542. Epub 2011 Dec 1.

24.

Genetic and epigenetic modifications of Sox2 contribute to the invasive phenotype of malignant gliomas.

Alonso MM, Diez-Valle R, Manterola L, Rubio A, Liu D, Cortes-Santiago N, Urquiza L, Jauregi P, Lopez de Munain A, Sampron N, Aramburu A, Tejada-Solís S, Vicente C, Odero MD, Bandrés E, García-Foncillas J, Idoate MA, Lang FF, Fueyo J, Gomez-Manzano C.

PLoS One. 2011;6(11):e26740. doi: 10.1371/journal.pone.0026740. Epub 2011 Nov 1.

25.

3'UTR-mediated gene silencing of the Mixed Lineage Leukemia (MLL) gene.

Gomez-Benito M, Loayza-Puch F, Oude Vrielink JA, Odero MD, Agami R.

PLoS One. 2011;6(10):e25449. doi: 10.1371/journal.pone.0025449. Epub 2011 Oct 5. Erratum in: PLoS One. 2011;6(11). doi:10.1371/annotation/d39cb963-9277-462f-8070-6409d6fcf484. Oude Vrielink, Joachim [corrected to Oude Vrielink, Joachim A F].

26.

Overexpression of GATA2 predicts an adverse prognosis for patients with acute myeloid leukemia and it is associated with distinct molecular abnormalities.

Vicente C, Vazquez I, Conchillo A, García-Sánchez MA, Marcotegui N, Fuster O, González M, Calasanz MJ, Lahortiga I, Odero MD.

Leukemia. 2012 Mar;26(3):550-4. doi: 10.1038/leu.2011.235. Epub 2011 Sep 9. No abstract available.

PMID:
21904383
27.

Down-regulation of EVI1 is associated with epigenetic alterations and good prognosis in patients with acute myeloid leukemia.

Vázquez I, Maicas M, Cervera J, Agirre X, Marin-Béjar O, Marcotegui N, Vicente C, Lahortiga I, Gomez-Benito M, Carranza C, Valencia A, Brunet S, Lumbreras E, Prosper F, Gómez-Casares MT, Hernández-Rivas JM, Calasanz MJ, Sanz MA, Sierra J, Odero MD.

Haematologica. 2011 Oct;96(10):1448-56. doi: 10.3324/haematol.2011.040535. Epub 2011 Jul 12.

28.

The role of the GATA2 transcription factor in normal and malignant hematopoiesis.

Vicente C, Conchillo A, García-Sánchez MA, Odero MD.

Crit Rev Oncol Hematol. 2012 Apr;82(1):1-17. doi: 10.1016/j.critrevonc.2011.04.007. Epub 2011 May 24. Review.

PMID:
21605981
29.

In vivo expression of an aberrant MYB-GATA1 fusion induces leukemia in the presence of GATA1 reduced levels.

Belloni E, Shing D, Tapinassi C, Viale A, Mancuso P, Malazzi O, Gerbino E, Dall'Olio V, Egurbide I, Odero MD, Bertolini F, Pelicci PG.

Leukemia. 2011 Apr;25(4):733-6. doi: 10.1038/leu.2010.317. Epub 2011 Jan 21. No abstract available. Erratum in: Leukemia. 2011 Dec;25(12):1922. Giuseppe Pelicci, P [corrected to Pelicci, P G].

PMID:
21252985
30.

PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect.

Cristóbal I, Garcia-Orti L, Cirauqui C, Alonso MM, Calasanz MJ, Odero MD.

Leukemia. 2011 Apr;25(4):606-14. doi: 10.1038/leu.2010.294. Epub 2011 Jan 14.

PMID:
21233840
31.

Silencing of hsa-miR-124 by EVI1 in cell lines and patients with acute myeloid leukemia.

Vázquez I, Maicas M, Marcotegui N, Conchillo A, Guruceaga E, Roman-Gomez J, Calasanz MJ, Agirre X, Prosper F, Odero MD.

Proc Natl Acad Sci U S A. 2010 Nov 2;107(44):E167-8; author reply E169-70. doi: 10.1073/pnas.1011540107. Epub 2010 Oct 7. No abstract available.

32.

EVI1 controls proliferation in acute myeloid leukaemia through modulation of miR-1-2.

Gómez-Benito M, Conchillo A, García MA, Vázquez I, Maicas M, Vicente C, Cristobal I, Marcotegui N, García-Ortí L, Bandrés E, Calasanz MJ, Alonso MM, Odero MD.

Br J Cancer. 2010 Oct 12;103(8):1292-6. doi: 10.1038/sj.bjc.6605874. Epub 2010 Sep 14.

33.

Spectral karyotyping (SKY).

Belloni E, Lahortiga I, Odero M, Di Fiore P, Pelicci P.

Ecancermedicalscience. 2010;4:181. doi: 10.3332/ecancer.2010.181. Epub 2010 Oct 13. No abstract available. Erratum in: Ecancermedicalscience. 2012;6:256. Bonnomi, E [removed].

34.

SETBP1 overexpression is a novel leukemogenic mechanism that predicts adverse outcome in elderly patients with acute myeloid leukemia.

Cristóbal I, Blanco FJ, Garcia-Orti L, Marcotegui N, Vicente C, Rifon J, Novo FJ, Bandres E, Calasanz MJ, Bernabeu C, Odero MD.

Blood. 2010 Jan 21;115(3):615-25. doi: 10.1182/blood-2009-06-227363. Epub 2009 Nov 16.

PMID:
19965692
35.

A novel t(7;13)(p12;q33 approximately q34) in AML-M2.

Gerbino E, Tapinassi C, Malazzi O, Micucci C, Calasanz MJ, Beltran-Heredia JM, Gasparini P, Odero MD, Pelicci PG, Belloni E.

Cancer Genet Cytogenet. 2009 Dec;195(2):198-200. doi: 10.1016/j.cancergencyto.2009.08.009. No abstract available.

36.

A new dic(7;12)(p12.21;p12.2) chromosome aberration in a case of acute myeloid leukemia.

Tapinassi C, Gerbino E, Malazzi O, Micucci C, Gasparini P, Najera MJ, Calasanz MJ, Odero MD, Pelicci PG, Belloni E.

Cancer Genet Cytogenet. 2008 Sep;185(2):102-5. doi: 10.1016/j.cancergencyto.2008.05.015.

PMID:
18722879
37.

In vitro validation of gamma-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia.

De Keersmaecker K, Lahortiga I, Mentens N, Folens C, Van Neste L, Bekaert S, Vandenberghe P, Odero MD, Marynen P, Cools J.

Haematologica. 2008 Apr;93(4):533-42. doi: 10.3324/haematol.11894. Epub 2008 Mar 5.

38.

Overexpression of sPRDM16 coupled with loss of p53 induces myeloid leukemias in mice.

Shing DC, Trubia M, Marchesi F, Radaelli E, Belloni E, Tapinassi C, Scanziani E, Mecucci C, Crescenzi B, Lahortiga I, Odero MD, Zardo G, Gruszka A, Minucci S, Di Fiore PP, Pelicci PG.

J Clin Invest. 2007 Dec;117(12):3696-707.

39.

Multicolor interphase cytogenetics for the study of plasma cell dyscrasias.

Sáez B, Martín-Subero JI, Odero MD, Prosper F, Cigudosa JC, Schoch R, Calasanz MJ, Siebert R.

Oncol Rep. 2007 Nov;18(5):1099-106.

40.

JAK2-V617F activating mutation in acute myeloid leukemia: prognostic impact and association with other molecular markers.

Vicente C, Vázquez I, Marcotegui N, Conchillo A, Carranza C, Rivell G, Bandrés E, Cristobal I, Lahortiga I, Calasanz MJ, Odero MD.

Leukemia. 2007 Nov;21(11):2386-90. Epub 2007 Jun 21. No abstract available. Erratum in: Leukemia. 2007 Dec;21(12):2576.

PMID:
17581610
41.

Simultaneous translocations of FGFR3/MMSET and CCND1 into two different IGH alleles in multiple myeloma: lack of concurrent activation of both proto-oncogenes.

Sáez B, Martín-Subero JI, Lahortiga I, Largo C, Larrayoz MJ, Odero MD, Prosper F, Cigudosa JC, Siebert R, Calasanz MJ.

Cancer Genet Cytogenet. 2007 May;175(1):65-8.

PMID:
17498561
42.

Duplication of the MYB oncogene in T cell acute lymphoblastic leukemia.

Lahortiga I, De Keersmaecker K, Van Vlierberghe P, Graux C, Cauwelier B, Lambert F, Mentens N, Beverloo HB, Pieters R, Speleman F, Odero MD, Bauters M, Froyen G, Marynen P, Vandenberghe P, Wlodarska I, Meijerink JP, Cools J.

Nat Genet. 2007 May;39(5):593-5. Epub 2007 Apr 15.

PMID:
17435759
43.

DNA profiling analysis of 100 consecutive de novo acute myeloid leukemia cases reveals patterns of genomic instability that affect all cytogenetic risk groups.

Suela J, Alvarez S, Cifuentes F, Largo C, Ferreira BI, Blesa D, Ardanaz M, García R, Marquez JA, Odero MD, Calasanz MJ, Cigudosa JC.

Leukemia. 2007 Jun;21(6):1224-31. Epub 2007 Mar 22.

PMID:
17377590
44.

A novel t(2;3)(p11;q27) in a case of follicular lymphoma.

Tapinassi C, Micucci C, Lahortiga I, Malazzi O, Gasparini P, Gorosquieta A, Odero MD, Belloni E.

Cancer Genet Cytogenet. 2007 Jan 1;172(1):70-3.

PMID:
17175383
45.

Identification of recurrent chromosomal breakpoints in multiple myeloma with complex karyotypes by combined G-banding, spectral karyotyping, and fluorescence in situ hybridization analyses.

Sáez B, Martín-Subero JI, Largo C, Martín MC, Odero MD, Prosper F, Siebert R, Calasanz MJ, Cigudosa JC.

Cancer Genet Cytogenet. 2006 Sep;169(2):143-9.

46.

Interphase FISH for the detection of breakpoints in IG loci and chromosomal changes with adverse prognostic impact in multiple myeloma with normal karyotypes.

Sáez B, Martín-Subero JI, Odero MD, Prosper F, Hernandez R, Cigudosa JC, Siebert R, Calasanz MJ.

Cancer Genet Cytogenet. 2006 Jun;167(2):183-5. No abstract available.

PMID:
16737923
47.

Geographic differences in the incidence of cytogenetic abnormalities of acute myelogenous leukemia (AML) in Spain.

Sierra M, Alonso A, Odero MD, Gonzalez MB, Lahortiga I, Pérez JJ, García JL, Gutiérrez NC, Calasanz MJ, San Miguel JF, Hernández JM.

Leuk Res. 2006 Aug;30(8):943-8. Epub 2006 Feb 28.

PMID:
16503352
48.

Coexistence of different clonal populations harboring the b3a2 (p210) and e1a2 (p190) BCR-ABL1 fusion transcripts in chronic myelogenous leukemia resistant to imatinib.

Agirre X, Román-Gómez J, Vázquez I, Jiménez-Velasco A, Larráyoz MJ, Lahortiga I, Andreu EJ, Márquez J, Beltrán de Heredia JM, Odero MD, Prósper F, Calasanz MJ.

Cancer Genet Cytogenet. 2005 Jul 1;160(1):22-6.

49.

Amplification of IGH/MYC fusion in clinically aggressive IGH/BCL2-positive germinal center B-cell lymphomas.

Martín-Subero JI, Odero MD, Hernandez R, Cigudosa JC, Agirre X, Saez B, Sanz-García E, Ardanaz MT, Novo FJ, Gascoyne RD, Calasanz MJ, Siebert R.

Genes Chromosomes Cancer. 2005 Aug;43(4):414-23.

PMID:
15852472
50.

p53 Aberrations do not predict individual response to fludarabine in patients with B-cell chronic lymphocytic leukaemia in advanced stages Rai III/IV.

Valgañón M, Giraldo P, Agirre X, Larráyoz MJ, Rubio-Martinez A, Rubio-Felix D, Calasanz MJ, Odero MD.

Br J Haematol. 2005 Apr;129(1):53-9.

Supplemental Content

Loading ...
Support Center